Last update :
11/08/2022
Anticancer drug   Rituximab  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Mabthera Argentina, Australia, Austria, Belgium, Chile, Colombia, Croatia, Denmark, Ecuador, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Japan, Luxembourg, Mexico, Morocco, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Romania, Saudi Arabia, Spain, Sweden, Switzerland, Tunisia, Turkey, United Arab Emirates, Venezuela
Novex Argentina
Reditux Chile, Peru
Rigetuxer Mexico
Rituxan Canada, Japan, United States of America
Rituximab New Zealand
Rixathon Belgium, Germany, Great Britain, Spain, Switzerland
Truxima Belgium, Canada, France, Germany, Great Britain, Spain, United States of America
Stability in solutions   Injection   Stability in solutions : Rituximab     
Container Solvent Concentration Temperature Storage Duration References
Glass None 10 mg/ml 2-4°C Protect from light
28 Day
4016
Level of evidence A+
Biosimilar
Glass None 10 mg/ml 23-25°C Protect from light
21 Day
4676
Level of evidence C

Glass None 10 mg/ml 25°C Protect from light
15 Day
4016
Level of evidence A+
Biosimilar
Polypropylene Sodium chloride 0,9% 1 mg/ml 2-8°C Not specified
31 Day
4040
Level of evidence A+
Biosimilar
Polyethylene Sodium chloride 0,9% 1 mg/ml 2-8°C Not specified
31 Day
4040
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 1 mg/ml 2-4°C Protect from light
28 Day
4016
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 1 mg/ml 2-8°C Protect from light
180 Day
3323
Level of evidence A+

Polyolefine Sodium chloride 0,9% 1 mg/ml 25°C Protect from light
15 Day
4016
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 1 mg/ml 4°C Protect from light
90 Day
2881
Level of evidence B+

Polyolefine Sodium chloride 0,9% 1 mg/ml 4°C Not specified
180 Day
3241
Level of evidence A+

Polyolefine Sodium chloride 0,9% 4 mg/ml 2-4°C Protect from light
28 Day
4016
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 4 mg/ml 25°C Protect from light
15 Day
4016
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 4 mg/ml 4°C Protect from light
90 Day
2881
Level of evidence B+

Not specified NaCl 0,9% or Glucose 5% 1 >> 4 mg/ml 2-8°C Protect from light
7 Day
3657
Manufacturer's stability data

Not specified NaCl 0,9% or Glucose 5% 1 >> 4 mg/ml 25°C Not specified
24 Hour
3657
Manufacturer's stability data

Polypropylen Syringe None 120 mg/ml 2-8°C Not specified
28 Day
2825
Level of evidence A+

Polypropylen Syringe None 120 mg/ml 30°C Light
24 Hour
2825
Level of evidence A+


  Mentions Légales